However, the humanized monoclonal CD47 antibody Hu5F9‐G4 is currently undergoing a phase I clinical trial in patients with advanced solid malignancies or lymphomas, and the results indicate that most toxic reactions are mild to moderate.44 This evidence concerns the gene CD47 and lymphoma.